secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2024-12-03T23:59:59+00:00
Accession:  0000950170-24-132452
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns reports positive Phase 1 CARDINAL data for TERN-701 in CML; MMR rate 50% at 3 months
--------------------------------------------------------------------------------

- 15 patients enrolled across 160mg, 320mg, 400mg QD; 14 of 15 remain on treatment as of Oct 28, 2024 cutoff.
- Cumulative MMR rate 50% (5/10) in non-T315i patients with ≥3 months treatment or MMR at baseline.
- No dose-limiting toxicities, AE-related discontinuations, dose reductions, or Grade 3+ treatment-related AEs.
- At 160mg and 320mg, free drug concentrations 4- and 8-fold above efficacious in vivo exposures.
- Dose expansion to start 1H25; longer-term MMR data expected in 4Q25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017024132452/0000950170-24-132452-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017024132452/tern-20241203.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-132452

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer